Probiotix Health PLC New commercial partnership agreement in China
15 August 2024 - 4:00PM
RNS Regulatory News
RNS Number : 4799A
Probiotix Health PLC
15 August 2024
15 August
2024
ProBiotix Health
plc
("ProBiotix" or the
"Company")
New commercial partnership agreement in
China
ProBiotix Health plc (AQUIS: PBX), a life
sciences business developing probiotics to support
cardiometabolic health, announces a new commercial partnership agreement for
InstaMelt with DanCare
Health homepage -
Dancarehealth). InstaMelt is
ProBiotix's newly developed food supplement dosage format that
offers innovative features for health brands and retailers. It will
be sold as a turnkey, direct dose stick solution that
melts instantly on the tongue and will be available in China through DanCare Health. InstaMelt will be launched
during Q4 2024 under the DanCare brand and represents a key
milestone in the Company's efforts to penetrate the Chinese market
with cardiometabolic supplement solutions containing
the IP-protected probiotic strain
LPLDL®.
DanCare Health was founded in
Denmark in 2003, with an initial focus on supplying high
quality branded products to the European
supplement industry. DanCare has since developed into a global
organisation having expanded well into China as one of their
strongholds taking off-set in their European manufactured quality
products. DanCare offers a
broad range of clinically documented, high quality supplements all
marketed globally under the company's DanCare
brand.
Steen
Andersen, CEO of ProBiotix Health plc, commented:
"DanCare is well-recognised in the Chinese market
as a high-quality innovative brand. With cardiovascular disease on
the rise and almost 155 million Chinese adults estimated to have
elevated cholesterol levels, there is an increasing consumer focus
on cardiometabolic health. With our product offering and
cooperation with a market leader like DanCare we are well
positioned to tap into this lucrative market over the years to
come."
The CEO and
spokesperson of DanCare Health commented:
"We are looking forward to this collaboration with
ProBiotix Health as our two companies share the same vision of
improving quality of life by bringing efficacious, high quality
innovate supplements to market. The significant clinical
documentation backing the strain
LPLDL®, in combination with the innovative
new stick dosage format and DanCare Health's strong market
position, will be an excellent addition to our product line in the
Chinese market. This sets high growth expectations for the product.
We are excited to see where this dynamic partnership
leads."
For further
information, please contact:
ProBiotix Health plc
|
https://probiotixhealth-ir.com/
|
Steen Andersen, Chief
Executive
|
Contact via Walbrook
below
|
|
|
Peterhouse
Capital Limited (Aquis Corporate Adviser and
Broker)
|
Tel: 020 7469
0930
|
Mark Anwyl
|
|
Duncan Vasey
|
|
|
|
Walbrook PR Ltd
|
probiotix@walbrookpr.com
|
Anna Dunphy
|
Mob: 07876
741 001
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NEXBXGDIDUBDGSS
Probiotix Health (AQSE:PBX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Probiotix Health (AQSE:PBX)
Historical Stock Chart
From Sep 2023 to Sep 2024